AFT Pharmaceuticals (AFT.NZ)

Executive Summary

AFT Pharmaceuticals is a New Zealand-based specialty pharmaceutical company with a dual business model: a distribution segment that markets in-licensed products across core markets, and an innovation segment focused on its patented Maxigesic® pain platform, which is now commercialized in over 40 countries. The company's commercial foundation provides stable revenue, while its pipeline targets high-value pain indications. Key pipeline assets include Combogesic® IV and Combogesic® tablets (both Phase 3 for acute/post-operative pain) and a Rapamycin cream (Phase 2 for port wine stains). With a market cap of ~$367M, AFT represents a balanced risk-reward profile, leveraging existing commercial infrastructure to de-risk pipeline development. Upcoming data readouts from the Combogesic trials could significantly expand its pain franchise, while the Rapamycin cream offers a novel, differentiated opportunity in dermatology.

Upcoming Catalysts (preview)

• Q1 2027Combogesic® IV Phase 3 data readout for acute pain70% success
• Q1 2027Combogesic® tablets Phase 3 data readout for post-operative pain70% success
• Q4 2027Rapamycin cream Phase 2 data readout for port wine stains40% success